Instead of a traditional IPO, Candid Therapeutics secured a NASDAQ listing and a massive capital infusion by merging with RallyBio. This reverse merger, coupled with a concurrent private investment, provides nearly $700 million in cash to fund operations through 2030, demonstrating a powerful alternative financing path to public markets.

While reverse mergers offer a faster route to public markets, they bypass the extensive investor meetings of a traditional IPO. This can result in a narrowly held story and weaker sell-side coverage, forcing companies to spend 6-12 months post-deal building the investor base they missed.

Reverse mergers are no longer a 'back door' listing method. Their acceptance by high-quality companies is driven by the concurrent PIPE financing, which recapitalizes the company and brings in a supportive, institutional shareholder base, mitigating the risk of inheriting a mismatched investor group.

Remix Therapeutics leveraged compelling Phase 1 data in a rare cancer with no approved treatments to accelerate its corporate strategy. Achieving a 43% overall response rate, far exceeding the 15% from prior therapies, provided the clinical validation necessary to pursue a reverse merger and go public.

Biotech firms are increasingly using reverse mergers paired with substantial PIPE financings ($200M+) as an alternative path to the public markets. This "IPO-esque" strategy offers speed and efficiency but may trade off the broader investor exposure gained through a traditional, lengthy roadshow process.

To tap into public market investors, Adaptin Bio merged with a 'Form 10' public shell company. This distinct route is not a SPAC as it doesn't raise money in an IPO. Instead, it provides a faster path to becoming a public reporting entity to attract a wider investor base.

When traditional venture funding dried up for Madrigal Pharmaceuticals, they found an unconventional path to capital and a public listing. They pursued a reverse merger with Cinta, a public company that had recently failed a Phase 3 trial and was seeking an exit. This "bake off" victory secured Madrigal $41 million.

Biotech companies are increasingly favoring reverse mergers over traditional IPOs. The process allows for confidential diligence with select funds, is faster, and sidesteps market volatility like election uncertainty. The previous stigma is fading as the quality of investor syndicates remains high.

The 'NewCo' model, which creates a Western company around in-licensed Asian assets, is now leveraging reverse mergers for a fast track to public markets. Slate Medicines' deal with Fulcrum Therapeutics exemplifies this trend, following similar moves by companies like Yarrow and Serapha, shortening the path from inception to public listing.